Skip to main content

Lynne Lederman, PhD, Medical Writer


Authored Items
Pomalyst (Pomalidomide): A New Third-Generation Immunomodulatory Drug for Relapsed and/or Refractory Multiple Myeloma
Lynne Lederman, PhD, Medical Writer
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen
Lynne Lederman, PhD, Medical Writer
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals in Payers' Guide, FDA Approvals
Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs
Lynne Lederman, PhD, Medical Writer
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals in Payers' Guide, FDA Approvals
Kyprolis: A New Treatment Option for Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent
Lynne Lederman, PhD, Medical Writer
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals in Payers' Guide, FDA Approvals
Last modified: May 3, 2013